for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Theratechnologies Inc

TH.TO

Latest Trade

4.45CAD

Change

-0.05(-1.11%)

Volume

11,215

Today's Range

4.35

 - 

4.72

52 Week Range

4.35

 - 

9.74

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.50
Open
4.72
Volume
11,215
3M AVG Volume
1.49
Today's High
4.72
Today's Low
4.35
52 Week High
9.74
52 Week Low
4.35
Shares Out (MIL)
76.95
Market Cap (MIL)
352.55
Forward P/E
-78.67
Dividend (Yield %)
--

Latest Developments

More

Theratechnologies Will Maintain Its Common Share Listing On Toronto Stock Exchange Under Symbol "TH"

Theratechnologies Reports Q3 Loss Per Share Of $0.02

European Commission Approves Trogarzo

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Theratechnologies Inc

Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition.

Industry

Biotechnology & Drugs

Contact Info

2015 Peel St 5th Floor

+1.514.3367800

http://www.theratech.com/

Executive Leadership

Dawn A. Svoronos

Independent Chairman of the Board

Luc Tanguay

President, Chief Executive Officer, Director

Philippe Dubuc

Chief Financial Officer, Senior Vice President

Jovan Antunovic

Senior Vice President and Chief Commercial Office

Christian Marsolais

Senior Vice President - Scientific Affairs and Alliances

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

0.007

2017

-0.186

2018

-0.047

2019(E)

-0.060
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.39
Price To Book (MRQ)
8.90
Price To Cash Flow (TTM)
1,063.21
Total Debt To Equity (MRQ)
178.97
LT Debt To Equity (MRQ)
167.71
Return on Investment (TTM)
-8.52
Return on Equity (TTM)
-6.50

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up